The Revolution in Diagnosis
Advanced prostate cancer encompasses locally advanced disease, metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic castration-resistant prostate cancer (mCRPC). Historically, doctors relied on conventional imaging (CI) methods such as standard computed tomography (CT) and bone scans (BS) for diagnosis, staging, and treatment response assessments.
The report underscores that NGI modalities are superior to conventional imaging for detecting metastatic disease. NGI achieves this superiority by offering enhanced sensitivity and specificity. PSMA-PET/CT, for instance, utilizes targeted radiotracers that bind specifically to Prostate-Specific Membrane Antigen (PSMA), a protein significantly overexpressed on prostate cancer cells. This allows NGI to detect microscopic metastatic disease that conventional scans might miss entirely.
NGI technologies are fundamentally changing how cancer is classified, moving from traditional anatomical staging to highly detailed molecular-based staging.
Key benefits of these advanced scans include:
- Superior Accuracy: PSMA-PET/CT outperforms WB-MRI in detecting nodal and bone metastases.
- Comprehensive View: WB-MRI is a powerful "one size fits all" technique that avoids ionizing radiation and excels in local staging and detecting bone metastases using detailed functional sequences.
- Guiding Therapy: NGI provides detailed biomarker information that helps physicians with metastasis detection, staging, assessing aggressiveness, and planning treatment.
Despite the massive leap in diagnostic accuracy, the central finding emphasized by Woo et al. is that the potential of NGI to fundamentally alter the disease course and improve long-term patient outcomes via treatment adaptations remains unproven.
The ability of NGI to detect disease with extremely high sensitivity, often locating lesions the size of a pinhead, creates a clinical challenge. It is not yet clear whether this increased detection of micrometastases actually represents clinically significant progression that affects a patient’s survival, or if it represents indolent disease that would not have impacted their lifespan anyway. This uncertainty means that prospective clinical trials are urgently required to determine if NGI-guided treatment genuinely improves clinical endpoints, such as overall survival and quality of life.
The report cautions against biases introduced by earlier, more accurate detection:
- Stage Migration: Detecting previously "invisible" disease shifts the patient’s official cancer stage earlier, which can artificially make survival statistics look better without improving the patient's actual health outcome.
- Overtreatment Risk: The high sensitivity of NGI could lead to the diagnosis and treatment of clinically insignificant lesions, increasing the risk of unnecessary interventions and associated side effects.
A New Role in Treatment Planning
The ESUR report details how NGI is moving beyond diagnosis and becoming an indispensable tool for treatment planning and selection.
One of the most significant applications is in PSMA-theranostics. PSMA-PET/CT acts as the patient selection tool for PSMA-targeted radioligand therapy (RLT). By visualizing PSMA expression across all disease sites, clinicians can identify which patients are likely to benefit from this "see it, treat it" approach. Patients with higher PSMA expression on their scans are generally considered more likely to respond well to the therapy.
Furthermore, NGI is refining radiotherapy (RT) planning. The high accuracy of PSMA-PET/CT enhances target identification, allowing for "precision radiotherapy. This enables dose escalation to specific diseased areas that were invisible to conventional imaging, potentially improving outcomes without significantly increasing side effects.
For patients with limited "oligometastatic" disease (typically five or fewer metastatic sites), NGI is crucial for guiding metastasis-directed therapy (MDT). Highly focused treatments, such as stereotactic body radiation therapy (SBRT), can be aimed directly at the few lesions identified on PSMA-PET or WB-MRI, a strategy that has shown promise for improving disease-free survival.
Guiding the Biopsy and Finding Aggressive Cancers
The report also highlights NGI's growing role in disease characterisation. For patients with metastatic disease, NGI can guide physicians to the most active and viable tumour sites for biopsy. This is critical for obtaining high-quality tissue samples suitable for genomic and molecular analysis. Studies show that targeting sites with high PSMA uptake (on PET) or specific functional features (on WB-MRI) significantly increases the success rate of biopsies for molecular sequencing.
NGI may also help identify aggressive disease variants, such as neuroendocrine prostate cancer, which can be less dependent on androgen-receptor signalling and may not express PSMA. In these cases, other imaging tools, like FDG-PET, may be more effective, demonstrating the need for a multi-modal imaging approach to understand a tumour's specific biology.
Rethinking Therapy Response: When Imaging and PSA Disagree
A crucial point for clinicians is the growing discordance between PSA levels and imaging findings. The report warns that biochemical response (a drop in PSA) may not fully capture the disease dynamics, especially in mCRPC. A recent systematic review found that PSA and PSMA-PET responses were discordant in approximately one-quarter of mCRPC cases.
This is partly because conventional imaging, particularly bone scans, is unreliable for monitoring treatment. BS-CT is known for the "flare phenomenon," where scans can appear to worsen as bone lesions are healing, falsely suggesting disease progression in a patient who is responding well.
Both PSMA-PET and WB-MRI overcome these limitations by directly imaging the tumour cells within the marrow spaces. To standardize this, new imaging-based response criteria are being validated:
- PSMA-PET: Criteria like RECIP (Response Evaluation Criteria in PSMA PET/CT) are being developed to measure changes in total PSMA-positive tumour volume.
- WB-MRI: The MET-RADS-P framework provides a therapy-agnostic way to assess the biological effects of treatment, such as changes in tumour cellularity and marrow composition.
Future Outlook: Precision and Caution
The European Society of Urogenital Radiology (ESUR) report confirms that PSMA-PET is now preferred and recommended for initial staging in newly diagnosed high-risk and locally advanced prostate cancer, often used as a front-line tool.
While NGI's strong ability to "rule-in" new disease sites makes escalating therapy safer, radiologists and clinicians must exercise caution with decisions regarding therapy de-escalations, as NGI only has a moderate "rule-out" capability.
The authors conclude that NGI technologies like PSMA-PET/CT and WB-MRI offer a profound advantage not just in initial detection, but also in guiding targeted biopsies, selecting patients for theranostics, and monitoring therapeutic response. However, until robust, long-term prospective studies deliver definitive evidence of improved survival, clinicians must continue to carefully weigh the benefits of enhanced detection against the risk of potentially harmful overtreatment and increased cost. The integration of these powerful tools into clinical practice requires collaborative effort and ongoing research to ensure that better detection truly leads to better patient outcomes.
Written by: Sungmin Woo,1 Luca Russo,2,3 Samuel J. Withey,4 Ailin Dehghanpour,5,6 Roberto García-Figueiras,7 Ivo G. Schoots,8,9 Giuseppe Petralia,10,11 Amish Lakhani,12 Tobias Penzkofer,13,14 Martina Pecoraro,5 Chen-Jiang Wu,15 Jochen Walz,16 Matthias Eiber,17 Wolfgang P. Fendler,18,19 Silke Gillessen,20,21 Raquel Perez-Lopez,22 Frédéric E. Lecouvet,23 Tara D. Barwick,24 Anwar R. Padhani,12 ESUR Prostate MRI Working Group
- Department of Radiology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA.
- Dipartimento Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Dipartimento Universitario di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Radiology, Royal Marsden NHS Foundation Trust, London, UK.
- Department of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
- Department of Radiology, Oncologic Imaging, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
- Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Division of Radiology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Department of Radiology, Mount Vernon Cancer Centre, Paul Strickland Scanner Centre, Northwood, UK.
- Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Berlin Institute of Health, Berlin, Germany.
- Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Urology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.
- Department of Nuclear Medicine, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
- Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany.
- German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany.
- Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
- Faculty of Biosciences Università della Svizzera Italiana, Lugano, Switzerland.
- Radiomics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
- Department of Medical Imaging, Institut de Recherche Expérimentale et Clinique, Institut du Cancer Roi Albert II, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
- Department of Radiology, Charing Cross Hospital, Imperial College Health Care NHS Trust, London, UK.
Read the Abstract